北京昭衍新药研究中心股份有限公司(股票代码:06127,下称“昭衍新药”)3月16日于港交所收市后公告称,集团成员公司通过中信证券及其附属公司进一步认购多项金融产品,截至公告日尚未到期的相关投资本金合计人民币4.6亿元。
北京昭衍新药研究中心股份有限公司(股票代码:06127,下称“昭衍新药”)3月16日于港交所收市后公告称,集团成员公司通过中信证券及其附属公司进一步认购多项金融产品,截至公告日尚未到期的相关投资本金合计人民币4.6亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.